Saturday audit · Friday global closes · next-week catalyst map

Aman's Global Market Intelligence — 2026-10-03

Generated 08:30 CEST (Europe/Rome) · Data cutoff 08:30 CEST / 06:30 UTC. Cash prices are Friday, October 2 closes. Markets are closed; there is no reliable weekend U.S. futures session, so no executable futures indication is claimed.

CAUTIOUS RISK-ON — TECH LEADS, LABOR COOLS, YIELDS STAY HIGH

Friday's weak U.S. employment report supported duration and growth equities, but the 10-year still ended near 5.28%, oil remains above $90, and global breadth was uneven. The cleanest evidence is in AI hardware/connectivity; speculative quantum and peptide-development equities weakened.

Executive dashboard

S&P 5007,722.72+0.73% Fri · −0.27% week

Nasdaq Composite27,190.86+1.19% · +0.45% week

Dow51,176.96+0.49% · −1.26% week

Russell 20002,832.90+0.94% · −0.16% week

VIX15.31−6.59% Fri · Cboe close

U.S. 2Y / 10Y4.83% / 5.28%Official Oct. 2 closes

Dollar index101.93−0.17% Fri

WTI / Brent$91.11 / $102.25WTI −1.90% · Brent −0.06%

Gold futures$4,162.30−0.95% Fri

Nikkei / Hang Seng68,309 / 23,972−0.94% / −2.60% Fri

Euro STOXX 506,238.50+1.02% Fri · −1.02% week

FTSE / DAX10,462 / 25,231+0.32% / +1.17% Fri

Market OHLCV: Yahoo Finance chart endpoints retrieved 08:31–08:33 CEST, cross-checked with Yahoo's closing report and the official Cboe VIX page. Rates: U.S. Treasury Oct. 2 curve. Weekly changes use five sessions; Shanghai's 3,842.20 reference is Sept. 30 because mainland markets were closed.

1 · Jobs miss, but no bond breakout lower

September payrolls rose only 29,000; unemployment was 4.2%, wages +0.1% m/m and +3.0% y/y, while July/August were revised down by 60,000 combined. Yet the official 10-year closed at 5.28%. BLS · Treasury

2 · AI connectivity led

NVDA +1.34%, COHR +5.59% and CRDO +4.03%; COHR and CRDO confirmed Friday watch triggers. MU fell 2.05% and never cleared its stated $1,108.72 trigger, showing selective—not indiscriminate—risk appetite.

3 · Speculation diverged

The quantum basket fell 0.5%–4.8% Friday and 3.8%–9.4% over five sessions. Peptide developers VKTX and GPCR lost 15.8% and 23.0% over five sessions. Falling VIX did not rescue narrative-heavy cohorts.

Market drivers and global map

Macro, central banks and geopolitics

Labor: the weak headline, slower wages and negative revisions reduce immediate Fed-hike pressure, but payroll growth averaged only 45,000 over the prior 12 months. Growth risk has risen. BLS primary release
Rates: Friday's official curve remained sharply upward from 2Y 4.83% to 10Y 5.28%. High long yields still constrain long-duration valuations. Treasury
Energy: WTI retreated to $91.11, but Brent held $102.25. A reported G7 plan to release 100m barrels over four months may cap spikes, while Middle East escalation remains the opposing tail risk. Yahoo market report
Fed week: Bowman speaks Tuesday; September FOMC minutes arrive Wednesday; Waller speaks Thursday. Fed calendar

Earnings, regulation and rotation

Breadth: all four U.S. indices rose Friday, but only Nasdaq finished the five-session span positive. Europe rebounded Friday after Thursday's selloff; Hong Kong remained weak.
Tesla: 486,532 Q3 deliveries and 464,391 production were filed; energy storage deployment was 13.7 GWh. Friday +4.65% on 1.48× recent volume. Deliveries are not earnings. SEC exhibit · Tesla IR
Regulation: the latest SEC release remains the Oct. 1 crypto-custody proposal; EMA's Oct. 2 list showed no new GLP-1/obesity approval relevant to the tracked basket. SEC · EMA
Rotation: optical/connectivity outperformed memory, power/cooling and quantum. Confirmation matters because COHR/CRDO now sit well above 20-day averages.

Region	Friday close	Five-session signal	Monday implication
U.S.	S&P +0.73%; Nasdaq +1.19%; Dow +0.49%; Russell +0.94%	Nasdaq +0.45%; others slightly to materially lower	Constructive technology tape, not broad weekly risk-on.
Europe	Euro STOXX 50 +1.02%; FTSE +0.32%; DAX +1.17%	−1.02%, −2.18%, −0.70%	Friday bounce repaired little of the week's damage.
Asia	Nikkei −0.94%; Hang Seng −2.60%; Shanghai closed	Nikkei +2.93%; HSI −3.19%	Japan leadership versus China/HK weakness; avoid treating Asia as one trade.

Theme dashboards

AI / semis / cloud / infrastructure

Leadership narrowed to compute and connectivity

NVDA closed $233.95, +1.34%, above its ~$223.79 20-day average and at a fresh 20-day intraday high of $237.88; volume was 1.24× recent average.
COHR closed $337.04 (+5.59%, 1.26× volume) and CRDO $218.64 (+4.03%, 1.22×), validating breakout watches; both are extended.
MU closed $1,074.89 (−2.05%): strong post-earnings evidence remains, but Friday rejected the $1,108 area.
VRT reclaimed its 20-day average by less than 0.5% on only 0.62× volume—insufficient confirmation.
Risks: 5%+ long yields, AI ROI, hyperscaler concentration, export controls, HBM/optical cyclicality and power constraints.

Quantum / extreme risk

Avoid stance passed its first audit

Friday: IONQ −0.50%, RGTI −2.37%, QBTS −4.77%, QUBT −2.50%. Five-session losses were 3.76%–9.42%.
QBTS and QUBT closed below yesterday's cited downside levels; RGTI also closed below $15.51. IONQ held above $43.55 by only $0.22.
IonQ's official events page lists no upcoming events; do not manufacture a near-term catalyst.
Government awards and product milestones are real but do not erase pre-profit cash burn, dilution, roadmap and modality risk.

Peptide / metabolic biotech

Clinical quality versus hostile tape

LLY −0.61% Friday and −3.43% over five sessions; NVO −0.21% and −3.81%.
Clinical-stage VKTX fell 15.80% and GPCR 22.99% over five sessions; both are high/binary risk and technically damaged.
Lilly's Phase 3 TRIUMPH-1 sponsor release reported 28.3% mean weight loss at 80 weeks on 12 mg retatrutide vs 2.2% placebo, but 11.3% discontinued for adverse events at 12 mg and dysesthesia was 12.5% vs 0.9%. Lilly primary release
No new relevant FDA/EMA approval was verified Friday. Efficacy does not resolve safety, CMC, access, pricing or competition.

Audit of the 2026-10-02 published calls

No hindsight rule: outcomes below apply yesterday's published triggers and invalidations to Friday's OHLC; a watch that triggered is not retroactively treated as a fill at the best price.

Prior call	Pre-stated test	Friday evidence	Audit verdict
MU conditional long	Hold $1,098.90 then clear $1,108.72	High $1,108.00; close $1,074.89, −2.05%	Not triggered. Discipline avoided a failed breakout.
NVDA conditional long	Hold above $232.29; stronger above $234.76	High $237.88; close $233.95, +1.34%	Triggered, partial follow-through. Cleared both intraday but did not close above $234.76; downgrade from clean breakout to hold/watch.
Quantum avoid	Avoid; weakness below named levels	All four fell; QBTS/QUBT/RGTI closed below cited levels	Worked. Avoiding chase preserved capital; no short fill or borrow claim.
COHR watch	Close above $323.23 then $332.86	Closed $337.04, +5.59%, 1.26× volume	Confirmed. Now extended; Monday requires pullback/hold, not chase.
CRDO watch	Close above $214.87 with volume	Closed $218.64, +4.03%, 1.22× volume	Confirmed. Intraday reversal from $231.59 argues for risk control.
VRT watch	Close above $252.10	Closed $252.18 on 0.62× volume	Marginal trigger only. Price passed by $0.08; volume did not confirm.
LLY / NVO watches	LLY reclaim $1,158.72; NVO reclaim $37.97 then $41.61	LLY $1,142.85; NVO $37.32	Not triggered. No bottom-fishing signal.

Ranked ideas · initial two-week paper tracking

Weekend posture: two conditional bullish setups, two avoids and five watches. Monday entries require live confirmation; weekend headlines can gap prices through every level. Confidence measures evidence quality, not probability of profit.

Bullish / constructive

#1 Conditional bullish

NVDA — NVIDIA

NASDAQ · mega-cap AI platform · high risk

Classification: trend-follow continuation, direction uncertain after intraday fade. Applicable horizons: day, 1–4 weeks; staged 3–12+ months.

Thesis / catalystFriday's jobs-driven risk-on move produced a 20-day intraday high with above-average volume; next week's rate path is the immediate catalyst.

Evidence / counterargument$233.95 remains above the ~$223.79 20-day average; $237.88 was rejected and 10Y remains 5.28%. Platform demand does not make valuation immune to yields.

Entry / confirmationMonday hold above $233.60, then close above $237.88 with SOX/connectivity breadth. Prefer an orderly retest, not an opening gap.

Invalidation / downsideDay close below $230; swing close below ~$223.79. Long-term invalidation: estimate cuts, export damage or durable margin erosion.

Fundamental / technicalLiquid category leader with positive 20-day trend; Friday volume 1.24× recent average. Latest reported quarter

Key risksChina/export rules, TSMC/packaging, hyperscaler concentration, custom silicon, AI ROI, power and multiple compression.

Thesis Confidence88

Risk80

Opportunity76

#2 Conditional bullish

COHR — Coherent

NYSE · large-cap photonics · very high risk

Classification: breakout follow-through only after digestion; direction uncertain. Applicable horizons: day and 1–4 weeks; staged 3–12+ months.

Thesis / catalystAI scale-out needs optical connectivity; the prior watch confirmed with a $337.04 close and 1.26× volume.

Evidence / counterargument+13.93% over five sessions and ~13% above its 20-day average is strong but extended. No Friday company release was found to justify extrapolating the move.

Entry / confirmationHold $332.86–$338 on a retest or form a higher low; alternatively close above Friday's $338.36 high on continued volume. No gap chase.

Invalidation / downsideClose below $319, then $315.43; swing thesis fails below ~$298.22 20-day average. Gaps can bypass stops.

Fundamental / technicalOptical demand exposure and fresh price/volume confirmation; monitor orders, margins, customer concentration and cash conversion. Coherent releases

Key risksMomentum reversal, unexplained move, optical cycle, leverage, integration, customer concentration and valuation.

Thesis Confidence76

Risk91

Opportunity72

Bearish / short / avoid

#1 Avoid chase · not a short

IONQ / QBTS / RGTI / QUBT

NYSE/Nasdaq · small/mid-cap, mostly pre-profit · extreme risk

Classification: tactical avoid; direction highly uncertain. Applicable horizons: day and 1–4 weeks; 3–12+ months only as venture-risk exposure. No borrow availability or fee claim.

Thesis / catalystFalling prices despite a risk-on Friday show relative weakness; IonQ lists no upcoming event on its official page.

Evidence / counterargumentFive-session losses: IONQ −3.76%, RGTI −8.46%, QBTS −9.42%, QUBT −8.71%. Counter: contracts, benchmarks or funding can gap shares higher.

Entry / confirmationNo naked short. Avoid strengthens below Friday lows: $43.15/$15.74/$15.15/$8.11 respectively.

Invalidation / downsideReconsider avoid on volume-backed closes above $45.34/$17.00/$16.11/$8.76. Short losses can be unlimited.

Fundamental lensDemand organic revenue, bookings conversion, customer acceptance, cash burn and fully diluted share evidence.

Key risksDilution, roadmap slippage, low revenue bases, modality competition, government conditions, thin liquidity and squeezes.

Thesis Confidence89

Risk98

Opportunity48

#2 Avoid falling knife

VKTX / GPCR — clinical obesity developers

NASDAQ · clinical-stage small/mid-cap biotech · extreme/binary risk

Classification: avoid until stabilization, not a short. Applicable horizons: day and 1–4 weeks; speculative 3–12+ months only after clinical/financing diligence.

Thesis / catalystBoth have peptide/metabolic optionality, but price is signaling risk: VKTX −15.80% and GPCR −22.99% in five sessions.

Evidence / counterargumentVKTX $29.94 below ~$32.88 20-day average; GPCR $27.67 below ~$36.37. Counter: positive data, partnerships or financing can cause discontinuous upside.

Entry / confirmationNo long until VKTX reclaims $31.09 then $32.88, or GPCR reclaims $29.25 then establishes a higher low. No naked biotech short.

Invalidation / downsideAvoid thesis weakens on verified positive clinical/regulatory evidence plus sustained volume-backed reclaims; downside can approach cash value after failure.

Biotech lensRequire endpoint statistics, safety, discontinuations, dose durability, CMC/scalability, cash runway and dilution analysis before upgrade.

Key risksBinary trial outcomes, tolerability, competitive differentiation versus Lilly/Novo, financing, CMC, regulatory path and gaps.

Thesis Confidence78

Risk97

Opportunity35

Watchlist — no active entry

#1 Memory watch

MU — Micron

NASDAQ · large-cap cyclical semiconductor · high risk. Classification/horizon: failed-breakout watch; day, 1–4 weeks, conditional 3–12+ months. Thesis/catalyst: record FY26 results and HBM demand remain strong evidence. Evidence/counter: Friday never cleared $1,108.72 and closed −2.05%, though still above ~$1,025 20-day average. Entry: close above $1,108.72 or stable retest near $1,050–$1,025. Invalidation/downside: close below $1,025; then $1,000. Risks: memory pricing, oversupply, capex, competitors, exports and rates. Micron results

Confidence91

Risk88

Opportunity68

#2 Interconnect watch

CRDO — Credo Technology

NASDAQ · mid/large-cap connectivity semiconductor · very high risk. Classification/horizon: confirmed but extended; day and 1–4 weeks. Thesis/catalyst: AI scale-out interconnect demand; Friday closed above the prior trigger on 1.22× volume. Evidence/counter: $218.64 is ~21% above its 20-day average, and the fade from $231.59 shows supply. Entry: hold $211.91–$214.87 or close above $231.59. Invalidation/downside: close below $211.91, then $200. Risks: concentration, competition, rich expectations, inventory and sharp beta. Credo IR

Confidence77

Risk93

Opportunity67

#3 Power/cooling watch

VRT — Vertiv

NYSE · large-cap infrastructure · high risk. Classification/horizon: marginal reclaim; 1–4 weeks and 3–12+ months. Thesis/catalyst: rack-density and data-center power needs. Evidence/counter: $252.18 barely cleared the prior $252.10 trigger, but on only 0.62× volume and after a weak week. Entry: hold above $252.10 and clear $254.80 with volume. Invalidation/downside: close below $248.54; then $238. Risks: project timing, working capital, customer concentration, competition, rates and valuation. Vertiv IR

Confidence79

Risk86

Opportunity64

#4 Delivery-to-earnings watch

TSLA — Tesla

NASDAQ · mega-cap auto/energy/AI · very high risk. Classification/horizon: event watch; day and 1–4 weeks through Oct. 21, not a fresh long-term call. Thesis/catalyst: 486,532 deliveries beat the cited market estimate; Q3 earnings are Oct. 21. Evidence/counter: +4.65% Friday on 1.48× volume, but deliveries do not reveal price/mix, margins or cash flow. Entry: hold $359.41 and close above $374.60; stronger above $386.83. Invalidation/downside: close below $359.41, then $345.88. Risks: pricing, margins, regulation, execution, autonomy claims, competition and valuation. Tesla IR

Confidence87

Risk91

Opportunity63

#5 Metabolic quality watch

LLY — Eli Lilly

NYSE · mega-cap pharma · high event risk. Classification/horizon: watch stabilization; 1–4 weeks and 3–12+ months. Thesis/catalyst: Phase 3 retatrutide efficacy supports franchise optionality. Evidence/counter: sponsor-reported TRIUMPH-1 was randomized, double-blind and placebo-controlled (n=2,339), but GI events, dysesthesia and 11.3% discontinuation at 12 mg matter; shares closed below their 20-day average. Entry: reclaim $1,164.92; stronger above $1,215. Invalidation/downside: below $1,136.66 then $1,113.29; long-term on regulatory, safety or CMC setback. Risks: approval, manufacturing, payer access, competition, pricing and valuation. Lilly data

Confidence91

Risk84

Opportunity66

Changes versus the 2026-10-02 report

Regime: neutral/cautious becomes cautious risk-on after the jobs miss, U.S. rally and VIX decline; high long yields and oil prevent a full risk-on label.
NVDA: remains constructive; Friday triggered the prior level and set a 20-day intraday high, but the close below $234.76 reduces breakout quality.
MU: downgraded from #1 bullish to watch after failing $1,108.72 and closing down 2.05%.
COHR/CRDO: both prior watches confirmed. COHR enters ranked constructive ideas; CRDO remains watch because of its intraday reversal and extension.
VRT: technically triggered by only $0.08 on weak volume; no promotion.
Quantum: avoid is strengthened after broad relative weakness; no short recommendation is added.
Peptides: LLY stays watch; NVO drops from the top-five watchlist after another 20-day low. VKTX/GPCR become an explicit avoid-falling-knife pair, not a short.
TSLA: added to watch after verified Q3 deliveries; Oct. 21 earnings is the next hard catalyst.

Important 7–30 day catalysts

Mon Oct. 5 · 16:00 CEST — U.S. ISM Services. Growth/prices/employment signal after weak payrolls. ISM

Tue Oct. 6 · 14:30 CEST — U.S. August trade balance. GDP tracking and tariff transmission. BEA

Tue Oct. 6 · 16:45 CEST — Fed Vice Chair for Supervision Bowman. Regulation/supervision speech; policy remarks are possible but not promised. Fed

Wed Oct. 7 · 20:00 CEST — FOMC minutes. September 15–16 meeting; reaction function after the jobs miss is the focus. Fed

Thu Oct. 8 · 10:30 / 14:30 CEST — Waller speech / initial claims. Rates and labor confirmation. Fed · NY Fed calendar

Fri Oct. 9 · 16:00 CEST — Preliminary Michigan sentiment. Inflation expectations matter with Brent above $100. NY Fed calendar

Oct. 14–16 — CPI, PPI/import prices, retail sales and industrial production. Critical inflation/growth cluster. BLS · Fed

Wed Oct. 21 · after U.S. close — Tesla Q3 results; 23:30 CEST webcast. Margin, price/mix, energy economics, capex and cash flow. Tesla IR

Oct. 27–28 — FOMC meeting. Oil, CPI and labor can materially change the path. Fed

Thu Oct. 29 · 13:30 CET — Q3 GDP advance and September PCE. Note Europe's clock change. BEA

No exact 7–30 day trial readout or FDA action date for the tracked peptide names was verified, and IonQ's official page lists no upcoming event. Therefore none is invented. Next week's verified macro calendar is heavier than the verified focus-company earnings calendar.

Bottom line by horizon

Day trade

Follow Friday's leaders only on confirmation

NVDA and COHR are preferred; MU needs a fresh reclaim. Do not chase opening gaps in COHR/CRDO or falling knives in quantum/biotech.

Biggest risk: weekend geopolitical/oil gap. Invalidation: NVDA below $230 or COHR below $319.

1–4 week swing

Quality over narrative

Favor liquid AI cash-flow exposure; keep position sizes smaller while the 10-year is above 5%. Tesla is event-defined into Oct. 21.

Biggest risk: CPI/oil reaccelerate yields despite weak labor. Invalidation: closes below stated 20-day/trend levels or estimate cuts.

3–12+ month investment

Stage entries; require economics

NVDA/AI infrastructure deserve staged diligence, not blanket buying. Quantum requires revenue/cash conversion; peptide biotech requires efficacy, safety, CMC, regulatory and runway evidence.

Biggest risk: normalized earnings fail to justify valuations. Invalidation: durable guide cuts, contract slippage, financing stress or regulatory setbacks.

Data quality & source controls

Verified

More than five live retrievals covered Yahoo market data/news, Cboe, BLS, Treasury, Fed, BEA, SEC/EDGAR, Tesla IR, ISM, EMA, ClinicalTrials.gov, IonQ and company IR sources.
All closes, five-session changes, 20-day averages/ranges and volume ratios were calculated from Yahoo daily OHLCV through Oct. 2.
Payroll details are from BLS; 2Y/10Y are official Treasury closes; VIX is cross-checked at Cboe.
Tesla delivery figures and earnings date are double-checked against both Tesla IR and the SEC exhibit.
Biotech efficacy/safety numbers are sponsor-reported and explicitly not treated as approval or peer-reviewed certainty.

Limitations

Saturday has no reliable live U.S. futures session. Weekend indications are intentionally omitted.
Yahoo daily feeds are delayed/reference data, not executable quotes. Volume ratios compare Friday with the preceding recent sessions.
Shanghai's latest reference is Sept. 30 due the mainland holiday; no Oct. 2 move is claimed.
Viking's events page retrieval was rate-limited and the attempted Micron events URL resolved to a generic blog with no calendar. Because exact company catalysts could not be verified there, none is asserted.
ClinicalTrials.gov search returned 34 retatrutide records but its rendered search view did not expose a dependable imminent readout date; Lilly IR was used for trial design/results, and no date was invented.
No borrow availability, fee, real-time spread, guaranteed stop execution or analyst rating is claimed.

Clickable source ledger

Yahoo Finance Oct. 2 closing report — market narrative, index closes, employment consensus comparison and energy development.
Cboe VIX — official/delayed Oct. 2 VIX close.
BLS September Employment Situation — payrolls, unemployment, wages, participation and revisions.
Treasury yield curve — Oct. 2 official rates.
Federal Reserve calendar; NY Fed indicator calendar; BEA schedule; ISM.
Tesla SEC exhibit; Tesla IR release.
Micron FY26 results; NVIDIA Q2 FY27; Coherent releases; Credo IR; Vertiv IR.
IonQ events; D-Wave releases.
Lilly TRIUMPH-1; ClinicalTrials.gov retatrutide search; EMA updates.
SEC press releases — current regulatory actions.

Cutoff: 2026-10-03 08:30 CEST · Saturday edition